References
- Habib M, Porter BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction. J Vis Exp. 2014 Feb;24(84):e51208.
- Centers for Disease Control and Prevention. Streptococcus pneumoniae [cited 2021 Jun 30. Available from: https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html
- Centers for Disease Control and Prevention. Chapter 11: penumococcal, manual for the surveillance of vaccine-preventable diseases 2020 [cited 2021 May]. Available from: https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html
- Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. Jama. 2001;285(13):1729–1735.
- Ogilvie I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009 Aug 6;27(36):4891–4904.
- Brown PD, Lerner SA. Community-acquired pneumonia. Lancet. 1998;352(9136):1295–1302.
- Jover F, Cuadrado J-M, Andreu L, et al. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med. 2008;19(1):15–21.
- Regev-Yochay G, Chowers M, Chazan B, et al. Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel. Hum Vaccin Immunother. 2018;14(10):2527–2532.
- Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged≥ 50 years with community-acquired pneumonia. J Infect Dis. 2013;208(11):1813–1820.
- Bonten MJ, Huijts SM, Bolkenbaas M, et al., Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 372(12): 1114–1125. 2015.
- Musher DM, Abers MS, Bartlett JG. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clinl Infect Dis. 2017;65(10):1736–1744.
- Beutels P, Postma MJ. Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res. 2001;1(1):47–58.
- WHO. Weekly epidemiological record. Relevé épidémiologique hebdomadaire cited 2020 Jul 20. Available from: https://www.who.int/wer/2007/wer8212.pdf?ua=1
- Bundesamt für Statistik (Federal Office for Statistics). Meldungen Infektionskrankheiten Stand am Ende der 1. Woche (08.01.2019) (Messages infectious diseases status at the end of the first week 08.Jan.2019 cited 2021 May 10. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/cc/Kampagnen/Bulletin/2019/BU_3_19.pdf.download.pdf/BU_3_19_DE.pdf
- Cafiero-Fonseca ET, Stawasz A, Johnson ST, et al. The full benefits of adult pneumococcal vaccination: a systematic review. PloS one. 2017;12(10):e0186903.
- Cutts F, Zaman S, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139–1146.
- Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
- Moore CE, Paul J, Foster D, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis. 2014;210(7):1001–1011.
- Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clinl Infect Dis. 2014;59(8):1066–1073.
- Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808.
- Bundesamt für Gesundheit (BAG) und Eidgenössische Kommission für Impffragen (EKIF). Pneumokokkenimpfung: empfehlungen zur Verhinderung von invasiven Pneumokokkenerkrankungen bei Risikogruppen 2014 [cited 8]. https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlung-verhinderung-invasive-pneumokokkenerkrankung-risikogruppen.pdf.download.pdf/bu-8-2014-pneumokokken-risikogruppen.pdf. Accessed 30 June 2021.
- Evers S, Ament A, Colombo G, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531–540.
- Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013(1). DOI:https://doi.org/10.1002/14651858.CD000422.pub3.
- Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–1460.
- Albrich W. Pneumokokken-Impfungen bei Kindern und Erwachsenen. Ther Umsch. 2016;73(5):235–240.
- The Food and Drug Administration (FDA). Pneumococcal 15-valent Conjugate Vaccine (VAXNEUVANCE) cited 2021 Sept 06. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance
- Dowell SF, Whitney CG, Wright C, et al. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis. 2003 May;9(5):573–579.
- Statistik der Bevölkerung und der Haushalte (BFS). cited 2021 May 4. Available from: https://www.pxweb.bfs.admin.ch/pxweb/de/px-x-0102010000_101/px-x-0102010000_101/px-x-0102010000_101.px
- Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Hum Vaccin Immunother. 2016;12(11):2953–2958.
- U.S. Department of health and human services oodpahp. IID-13.2 Increase the percentage of noninsti tutionalized high-risk adults aged 18 to 64 years who are vaccinated against pneumococcal disease cited 2021 Sept 06. Available from: https://www.healthypeople.gov/2020/data-search/Search-the-Data?objid=4671
- Wagenvoort GH, Knol MJ, de Melker HE, et al., Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. Vaccine. 34(3): 334–340. 2016 .
- Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008-2014. BMC Health Serv Res. 2018 Sep 14;18(1):715.
- van Hoek AJ, Andrews N, Waight PA, et al., The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 65(1): 17–24. 2012.
- Mangen M-J-J, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–1416.
- Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010 Jul;61(2):114–124.
- Bundesamt für Gesundheit (BAG). Pneumokokkenerkrankungen 2012. 2013;25.04.2013.
- Eidgenössisches Departement des Innern EDI BfGB. Prevenar 13 cited 2020 Jul 23. Available from: http://www.spezialitaetenliste.ch/
- TARMED 2020 cited 2020 Jul 23. Available from: https://www.tarmed-browser.ch/de
- Bundesamt für Statistik (Federal Office for Statistics). Medizinische Statistik der Krankenhäuser:Anzahl Fälle und durchschnittliche Aufenthaltsdauer (DAD) nach Altersklasse und Diagnosekode (Medical statistics of the hospitals: number of cases and average length of stay (DAD) by age group and diagnosis code) 2018 cited 2020 Jul 23. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/kataloge-datenbanken/tabellen.assetdetail.10787003.html
- SwissDRG. cited 2020 Jul 23. Available from: https://grouper.swissdrg.org/swissdrg/single?locale=de
- HSK. Einkaufsgemeinschaft HSK Benchmark Swiss DRG Tarifjahr 2020 cited 2021 Jun 30. Available from: https://ecc-hsk.info/application/files/4115/7013/0089/Benchmark-Dokument_TJ2020_DE.pdf
- Suisse T. Tarifsuisse-Benchmarking für die DRG-Tarife 2020. cited 2021 Jun 30. Available from: https://www.tarifsuisse.ch/fileadmin/sas_content/tarifsuisse_BM_2020_DRG_d_15.10_01.pdf
- Spitalbenchmark. SpitalBenchmark. Kosten- und Leistungsvergleiche cited 2021 Jun 30. Available from: https://www.spitalbenchmark.ch/
- Blank PR, Szucs TD. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine. 2012;30(28):4267–4275.
- Federal Office of Statistics. Beschäftigungsgrad nach Geschlecht, Nationalität, Altersgruppen, Familientyp (Degree of employment according to gender, nationality, age groups, family type) 2020 cited 2020 Jul 23. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/arbeit-erwerb/erhebungen/sake/publikationen-ergebnisse.assetdetail.12647323.html
- Ess SM, Schaad UB, Gervaix A, et al. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 2003;21(23):3273–3281.
- Ruedin HJ, Ess S, Zimmermann H, et al. Invasive meningococcal and pneumococcal disease in Switzerland: cost–utility analysis of different vaccine strategies. Vaccine. 2003;21(27–30):4145–4152.
- Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–968.
- Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020 Feb 11;38(7):1770–1777.
- Bennett JE, Sumner W, Downs SM, et al. Parents’ utilities for outcomes of occult bacteremia. Arch pediatr adolesc med. 2000;154(1):43–48.
- Des Portes V. Long-term follow-up of bacterial meningitis - sequels in children and adults: incidence, type, and assessment issues. Med Mal Infect. 2009 Jul-Aug;39(7–8):572–580.
- Hauser C, Kronenberg A, Allemann A, et al. Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. Eurosurveillance. 2016;21(21):30239.
- Ott SR, Hauptmeier BM, Ernen C, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J. 2012;39(3):611–618.
- Heininger U, Pillsbury M, Samant S, et al. Health impact and cost-effectiveness assessment for the introduction of universal varicella vaccination in switzerland. Pediatr Infect Dis J. 2021;40(6):e217–e221.
- Banz K, Iseli A, Aebi C, et al. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccines. 2009;5(12):847–857.
- OANDA. Currency Converter/Foreign Exchange Rates cited 2021 Jun 27. Available from: https://www1.oanda.com/currency/converter/
- Federal Office of Statistics. Gross Domestic Product cited 2021 Jun 27. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/volkswirtschaft/volkswirtschaftliche-gesamtrechnung/bruttoinlandprodukt.assetdetail.14347461.html
- Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2021;40:162–172.
- Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539.
- Peterson JT, Stacey HL, MacNair JE, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults≥ 65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548.
- Horácio AN, Silva-Costa C, Lopes JP, et al. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 2016;7:1616.
- Galanis I, Lindstrand A, Darenberg J, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208–1218.
- Oligbu G, Collins S, Andrews N, et al. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006–2014. Clinl Infect Dis. 2017;65(7):1191–1198.
- Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine. 2014;32(21):2399–2405.
- Treskova M, Scholz SM, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. Pharmaco Economics. 2019;37:1–35.
- Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.
- Smith M, Stuart J, Andrews N, et al. Invasive pneumococcal infection in South and West England. Epidemiol Infect. 1998;120(2):117–123.
- Yahiaoui RY, Bootsma HJ, den Heijer CDJ, et al. Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis. 2018 Aug 29;18(1):440.